Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 10 | 2015 | 137 | 2.580 |
Why?
|
| Cell Proliferation | 11 | 2021 | 936 | 1.620 |
Why?
|
| Lectins | 5 | 2011 | 38 | 1.540 |
Why?
|
| Glioblastoma | 4 | 2015 | 150 | 1.500 |
Why?
|
| Glycoproteins | 4 | 2011 | 192 | 1.340 |
Why?
|
| Breast Neoplasms | 6 | 2021 | 1113 | 1.330 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 60 | 1.050 |
Why?
|
| Cell Line, Tumor | 15 | 2021 | 1360 | 1.030 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2017 | 166 | 1.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2017 | 47 | 1.000 |
Why?
|
| RNA Recognition Motif Proteins | 3 | 2021 | 5 | 0.980 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 3 | 2021 | 8 | 0.980 |
Why?
|
| Endothelial Cells | 5 | 2012 | 175 | 0.940 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 201 | 0.940 |
Why?
|
| RNA Helicases | 3 | 2021 | 88 | 0.930 |
Why?
|
| DNA Helicases | 3 | 2021 | 185 | 0.850 |
Why?
|
| Signal Transduction | 9 | 2020 | 2881 | 0.820 |
Why?
|
| Neoplasms | 5 | 2013 | 1221 | 0.770 |
Why?
|
| Adipokines | 5 | 2011 | 26 | 0.760 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 481 | 0.750 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2021 | 26 | 0.740 |
Why?
|
| Cadherins | 3 | 2017 | 67 | 0.740 |
Why?
|
| beta Catenin | 1 | 2021 | 85 | 0.720 |
Why?
|
| RNA, Small Interfering | 8 | 2020 | 849 | 0.720 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2021 | 177 | 0.690 |
Why?
|
| Cell Movement | 6 | 2020 | 419 | 0.690 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1289 | 0.680 |
Why?
|
| Carrier Proteins | 2 | 2015 | 714 | 0.650 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2015 | 13 | 0.590 |
Why?
|
| Proteoglycans | 3 | 2011 | 33 | 0.570 |
Why?
|
| Epithelial Cells | 2 | 2011 | 374 | 0.540 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 275 | 0.540 |
Why?
|
| Animals | 20 | 2021 | 19494 | 0.530 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 200 | 0.520 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2015 | 4 | 0.520 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.520 |
Why?
|
| Berberine | 1 | 2015 | 3 | 0.520 |
Why?
|
| DNA Damage | 3 | 2018 | 272 | 0.510 |
Why?
|
| Smad Proteins | 1 | 2015 | 19 | 0.510 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 73 | 0.490 |
Why?
|
| Mice, Inbred BALB C | 6 | 2021 | 880 | 0.490 |
Why?
|
| Mice | 14 | 2021 | 10192 | 0.490 |
Why?
|
| Autophagy | 1 | 2017 | 205 | 0.480 |
Why?
|
| Laminin | 2 | 2011 | 74 | 0.480 |
Why?
|
| Chitinase-3-Like Protein 1 | 5 | 2011 | 10 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 15 | 0.470 |
Why?
|
| Collagen | 2 | 2011 | 120 | 0.470 |
Why?
|
| Mice, SCID | 6 | 2011 | 501 | 0.460 |
Why?
|
| Mice, Nude | 5 | 2021 | 257 | 0.450 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 305 | 0.410 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 337 | 0.380 |
Why?
|
| Hormones | 1 | 2011 | 56 | 0.380 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 26 | 0.380 |
Why?
|
| Cell Polarity | 1 | 2011 | 110 | 0.370 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 79 | 0.370 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 1126 | 0.370 |
Why?
|
| Humans | 26 | 2021 | 58855 | 0.370 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 637 | 0.360 |
Why?
|
| Autoantigens | 1 | 2011 | 125 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 240 | 0.350 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 78 | 0.350 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 15 | 0.350 |
Why?
|
| Ribonucleoproteins | 1 | 2011 | 112 | 0.350 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 220 | 0.350 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 192 | 0.330 |
Why?
|
| Myosin Light Chains | 1 | 2008 | 7 | 0.320 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 13 | 0.320 |
Why?
|
| Peptides | 1 | 2012 | 545 | 0.320 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 20 | 0.320 |
Why?
|
| Paclitaxel | 1 | 2009 | 88 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2008 | 5 | 0.310 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 17 | 0.310 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 275 | 0.300 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 452 | 0.300 |
Why?
|
| Muscle Proteins | 1 | 2008 | 109 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 184 | 0.290 |
Why?
|
| Cytoplasm | 1 | 2008 | 270 | 0.280 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 221 | 0.270 |
Why?
|
| Transfection | 3 | 2015 | 670 | 0.270 |
Why?
|
| Apoptosis | 4 | 2018 | 1034 | 0.270 |
Why?
|
| Mesoderm | 1 | 2006 | 83 | 0.260 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 194 | 0.260 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 325 | 0.260 |
Why?
|
| Enediynes | 2 | 2016 | 2 | 0.260 |
Why?
|
| Aminoglycosides | 2 | 2016 | 8 | 0.260 |
Why?
|
| Telomerase | 1 | 2004 | 30 | 0.240 |
Why?
|
| HCT116 Cells | 3 | 2016 | 49 | 0.230 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 62 | 0.230 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 115 | 0.230 |
Why?
|
| Neovascularization, Physiologic | 1 | 2004 | 102 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 453 | 0.220 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 171 | 0.220 |
Why?
|
| Cell Line | 4 | 2011 | 2011 | 0.220 |
Why?
|
| Female | 9 | 2021 | 30564 | 0.210 |
Why?
|
| Blotting, Western | 2 | 2015 | 591 | 0.210 |
Why?
|
| Antigens, CD | 2 | 2017 | 341 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2016 | 212 | 0.200 |
Why?
|
| Neoplasm Transplantation | 3 | 2014 | 157 | 0.190 |
Why?
|
| Drug Combinations | 2 | 2011 | 140 | 0.190 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 64 | 0.180 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 34 | 0.180 |
Why?
|
| Enzyme Activation | 2 | 2013 | 351 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 71 | 0.170 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 846 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2012 | 304 | 0.170 |
Why?
|
| Phosphorylation | 2 | 2013 | 858 | 0.160 |
Why?
|
| Pyridazines | 1 | 2018 | 6 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 24 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 43 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2010 | 58 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 52 | 0.140 |
Why?
|
| Disease Progression | 2 | 2011 | 1030 | 0.140 |
Why?
|
| RNA Interference | 2 | 2011 | 587 | 0.140 |
Why?
|
| Comet Assay | 1 | 2015 | 11 | 0.130 |
Why?
|
| Cellular Senescence | 1 | 2016 | 103 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 23 | 0.130 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2015 | 6 | 0.130 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 64 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 133 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 192 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2020 | 488 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 59 | 0.110 |
Why?
|
| Amino Alcohols | 1 | 2013 | 1 | 0.110 |
Why?
|
| Rituximab | 1 | 2014 | 82 | 0.110 |
Why?
|
| Lysophospholipids | 1 | 2013 | 22 | 0.110 |
Why?
|
| Sphingosine | 1 | 2013 | 22 | 0.110 |
Why?
|
| Ceramides | 1 | 2013 | 23 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 47 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 43 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 693 | 0.100 |
Why?
|
| Cinnamates | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cisplatin | 1 | 2012 | 119 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2012 | 189 | 0.100 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 16 | 0.100 |
Why?
|
| Prolactin | 1 | 2011 | 40 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 219 | 0.100 |
Why?
|
| Antibody Specificity | 1 | 2011 | 99 | 0.100 |
Why?
|
| Milk | 1 | 2011 | 50 | 0.100 |
Why?
|
| Caseins | 1 | 2011 | 41 | 0.100 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 42 | 0.090 |
Why?
|
| Gamma Rays | 1 | 2011 | 31 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2011 | 32 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 97 | 0.090 |
Why?
|
| Lactation | 1 | 2011 | 70 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 31 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 522 | 0.090 |
Why?
|
| Vimentin | 1 | 2010 | 18 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 2011 | 187 | 0.090 |
Why?
|
| Biglycan | 1 | 2009 | 2 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 14 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 265 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 30 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 70 | 0.080 |
Why?
|
| Vincristine | 1 | 2009 | 26 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 7 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 62 | 0.080 |
Why?
|
| Stress Fibers | 1 | 2008 | 2 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 565 | 0.080 |
Why?
|
| Survival Rate | 1 | 2011 | 783 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 86 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 32 | 0.080 |
Why?
|
| Plasmids | 1 | 2009 | 279 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2008 | 211 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 379 | 0.080 |
Why?
|
| Benzamides | 1 | 2008 | 51 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 804 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 103 | 0.070 |
Why?
|
| Piperazines | 1 | 2008 | 95 | 0.070 |
Why?
|
| Insulin | 1 | 2011 | 682 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2008 | 140 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 122 | 0.070 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2018 | 44 | 0.070 |
Why?
|
| Receptors, Vitronectin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Biomarkers | 1 | 2011 | 1199 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 90 | 0.060 |
Why?
|
| Integrins | 1 | 2006 | 108 | 0.060 |
Why?
|
| Receptor, TIE-1 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2004 | 7 | 0.060 |
Why?
|
| Transformation, Genetic | 1 | 2004 | 27 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2004 | 111 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 788 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1136 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 688 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2020 | 17 | 0.050 |
Why?
|
| Nanoconjugates | 1 | 2020 | 5 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 117 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2020 | 63 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 5922 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 113 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2016 | 24 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 73 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
|
| Male | 2 | 2020 | 27275 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 806 | 0.030 |
Why?
|
| Adult | 1 | 2011 | 15602 | 0.030 |
Why?
|
| Middle Aged | 1 | 2011 | 16127 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 31 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 38 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 31 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2014 | 18 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2020 | 698 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 132 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 654 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 98 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 198 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 105 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1460 | 0.020 |
Why?
|